Jane Street Group LLC Buys 3,725 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Jane Street Group LLC grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 7.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 54,282 shares of the company’s stock after acquiring an additional 3,725 shares during the quarter. Jane Street Group LLC’s holdings in Omnicell were worth $2,417,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in OMCL. Smartleaf Asset Management LLC grew its stake in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. bought a new stake in Omnicell in the fourth quarter worth $37,000. Van ECK Associates Corp boosted its holdings in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new stake in Omnicell in the fourth quarter worth $53,000. Finally, First Horizon Advisors Inc. boosted its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on OMCL. Wells Fargo & Company raised Omnicell from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $31.00 to $35.00 in a report on Wednesday. JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, May 3rd. Finally, Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and an average price target of $46.50.

Omnicell Trading Down 2.3%

OMCL opened at $28.08 on Friday. The business has a fifty day moving average price of $31.57 and a 200 day moving average price of $39.64. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 104.00, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. During the same period in the prior year, the business posted $0.03 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.